HYPAQUE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
HYPAQUE by GE HealthCare is clinical pharmacology retrograde introduction of hypaque-cysto solution provides radiopacity of the contents of the urinary bladder. First approved in 1954.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYPAQUE is a water-soluble iodinated contrast medium (diatrizoate meglumine) administered by retrograde injection into the urinary bladder for radiographic visualization during cystourethrography and micturition studies. It provides radiopacity to detect cystoureteric reflux and evaluate lower urinary tract function without significant systemic absorption. The drug works by remaining localized in the urinary tract while delivering radiopacity for fluoroscopic imaging.
LOE Approaching
Product approaching loss of exclusivity with minimal linked career opportunity signals, indicating limited team growth and potential headcount transitions.
Mechanism of Action
CLINICAL PHARMACOLOGY Retrograde introduction of HYPAQUE-CYSTO solution provides radiopacity of the contents of the urinary bladder. When used during micturation as a function test, it also opacifies the bladder neck and lower urinary tract. Continuous fluoroscopic and monitoring of urinary bladder…
Worked on HYPAQUE at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.